SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006; 12: e1e2.
  • 2
    Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106: 30683072.
  • 3
    Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88: 107115.
  • 4
    Hunt SA, Abraham WT, Chin MH et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112: e154e235.
  • 5
    Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002;347: 305313.
  • 6
    Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162: 18671872.
  • 7
    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89: 25482556.
  • 8
    Kawanami D, Maemura K, Takeda N et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004;314: 415419.
  • 9
    Imai J, Katagiri H, Yamada T et al. Cold exposure suppresses serum adiponectin levels through sympathetic nerve activation in mice. Obesity (Silver Spring) 2006;14: 11321141.
  • 10
    Liao Y, Takashima S, Maeda N et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005;67: 705713.
  • 11
    Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA 2005;294: 334341.
  • 12
    Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1975;110: 281290.
  • 13
    Roubicek T, Bartlova M, Krajickova J et al. Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease. Nutrition 2009;25: 762768.
  • 14
    Diabetes Care Committee. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 Suppl 1: S5S20.
  • 15
    Sorlie P. Cardiovascular diseases and death following myocardial infarction and angina pectoris: Framingham study 20-year follow-up. In: Kannel WB, Gordon T (eds). The Framingham Study: An Epidemiologic Investigation of Cardiovascular Disease. Government Printing Office: Washington, D.C., 1977, pp 771247.
  • 16
    Keaney JF Jr, Larson MG, Vasan RS et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23: 434439.
  • 17
    Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107: 14861491.
  • 18
    Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58: 10721083.
  • 19
    Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57: 450458.
  • 20
    Wade MR, Chandraratna PA, Reid CL, Lin SL, Rahimtoola SH. Accuracy of nondirected and directed M-mode echocardiography as an estimate of left atrial size. Am J Cardiol 1987;60: 12081211.
  • 21
    Sundström J, Sullivan L, Selhub J et al. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J 2004;25: 523530.
  • 22
    Hirschler V, Acebo HL, Fernandez GB et al. Influence of obesity and insulin resistance on left atrial size in children. Pediatr Diabetes 2006;7: 3944.
  • 23
    Knutsen KM, Stugaard M, Michelsen S, Otterstad JE. M-mode echocardiographic findings in apparently healthy, non-athletic Norwegians aged 20–70 years. Influence of age, sex and body surface area. J Intern Med 1989;225: 111115.
  • 24
    Rutter MK, Parise H, Benjamin EJ et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003;107: 448454.
  • 25
    Gu L, Pandey V, Geenen DL, Chowdhury SA, Piano MR. Cigarette smoke-induced left ventricular remodelling is associated with activation of mitogen-activated protein kinases. Eur J Heart Fail 2008;10: 10571064.
  • 26
    Gerdts E, Oikarinen L, Palmieri V et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002;39: 739743.
  • 27
    Frankel DS, Vasan RS, D'Agostino RB Sr et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009;53: 754762.
  • 28
    Burnett MS, Lee CW, Kinnaird TD et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005;182: 241248.
  • 29
    Ran J, Hirano T, Fukui T et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metab Clin Exp 2006;55: 478488.
  • 30
    Ohara T, Kim J, Asakura M et al. Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects. Hypertens Res 2008;31: 825831.
  • 31
    Ebinç H, Ebinç FA, Ozkurt ZN et al. Impact of adiponectin on left ventricular mass index in non-complicated obese subjects. Endocr J 2008;55: 523528.
  • 32
    Kozakova M, Muscelli E, Flyvbjerg A et al. Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab 2008;93: 28112818.
  • 33
    Abhayaratna WP, Seward JB, Appleton CP et al. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 2006;47: 23572363.
  • 34
    Pritchett AM, Mahoney DW, Jacobsen SJ et al. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol 2005;45: 8792.
  • 35
    Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004;10: 13841389.
  • 36
    Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291: 17301737.
  • 37
    Shibata R, Izumiya Y, Sato K et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 2007;42: 10651074.
  • 38
    Takeishi Y, Niizeki T, Arimoto T et al. Serum resistin is associated with high risk in patients with congestive heart failure—a novel link between metabolic signals and heart failure. Circ J 2007;71: 460464.
  • 39
    Biolo A, Shibata R, Ouchi N et al. Determinants of adiponectin levels in patients with chronic systolic heart failure. Am J Cardiol 2010;105: 11471152.
  • 40
    Ohmori R, Momiyama Y, Kato R et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005;46: 379380.
  • 41
    Bo S, Gambino R, Pagani A et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005;29: 13151320.
  • 42
    Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27: 24502457.
  • 43
    Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med 2003;81: 218226.
  • 44
    Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001;409: 307312.
  • 45
    Ogawa R, Tanaka C, Sato M et al. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. Biochem Biophys Res Commun 2010;398: 723729.